{"entity":{"id":"nct06788171","kind":"trial","name":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","aka":[],"tldr":"A phase 2 trial of bevacizumab (glioblastoma use), capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and sintilimab in colorectal cancer, run by Fujian Cancer Hospital, not yet recruiting.","summary":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM is a phase 2, interventional study registered as NCT06788171 by Fujian Cancer Hospital, with a registry enrolment figure of 35 participants, started 2025-03-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy; Bevacizumab; Capecitabine; Oxaliplatin; Sintilimab. Conditions listed: Colorectal Cancer Liver Metastasis. Primary outcome: Progression-free-Survival. Colorectal eligibility wording from the registry: \"Pathologically confirmed colorectal cancer with liver metastases (stage M1)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06788171","url":"https://clinicaltrials.gov/study/NCT06788171"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","sbrt"],"targets":[],"drugs":["bevacizumab-glioma","capecitabine","folfox","sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06788171","phase":"2","setting":"A Phase II Trial of PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy) Combined With PD-1 Ab and Chemotherapy Plus Bevacizumab for Colorectal Cancer Liver Metastasis","sponsor":"Fujian Cancer Hospital","enrolled":35,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06788171/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}